Co-Diagnostics, Inc. Revenue from Contract with Customer, Including Assessed Tax
Co-Diagnostics, Inc. (CODX) reported Revenue from Contract with Customer, Including Assessed Tax of $145.38 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2025-11-13
- Co-Diagnostics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $145.38K, a 77.32% decline year-over-year.
- Co-Diagnostics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-06-30 was $162.91K, a 93.87% decline year-over-year.
- Co-Diagnostics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-03-31 was $50.28K, a 89.25% decline year-over-year.
- Co-Diagnostics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2024-12-31 was $149.32K, a 95.80% decline year-over-year.
- Co-Diagnostics, Inc. revenue from contract with customer, including assessed tax for fiscal 2024 was $3.92M, a 42.53% decline from fiscal 2023.
- Co-Diagnostics, Inc. revenue from contract with customer, including assessed tax for fiscal 2023 was $6.81M, a 80.09% decline from fiscal 2022.
- Co-Diagnostics, Inc. revenue from contract with customer, including assessed tax for fiscal 2022 was $34.22M, a 65.04% decline from fiscal 2021.
- Co-Diagnostics, Inc. revenue from contract with customer, including assessed tax for fiscal 2021 was $97.89M, a 31.30% increase from fiscal 2020.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-09-30 | $145.38K 10-Q · filed 2025-11-13 | $308.29K derived: sum of 2 quarters · filed 2025-11-13 | $358.57K 10-Q · filed 2025-11-13 | $507.89K derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | $162.91K 10-Q · filed 2025-08-14 | $213.19K 10-Q · filed 2025-08-14 | $362.51K derived: sum of 3 quarters · filed 2025-08-14 | $1.00M derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-03-31 | $50.28K 10-Q · filed 2025-05-08 | $199.60K derived: sum of 2 quarters · filed 2025-05-08 | $840.74K derived: sum of 3 quarters · filed 2025-11-13 | $3.50M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-12-31 | $149.32K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $790.47K derived: sum of 2 quarters · filed 2025-11-13 | $3.45M derived: sum of 3 quarters · filed 2025-11-13 | $3.92M 10-K · filed 2025-03-27 |
| 2024-09-30 | $641.14K 10-Q · filed 2025-11-13 | $3.30M derived: sum of 2 quarters · filed 2025-11-13 | $3.77M 10-Q · filed 2025-11-13 | $7.32M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $2.66M 10-Q · filed 2025-08-14 | $3.12M 10-Q · filed 2025-08-14 | $6.68M derived: sum of 3 quarters · filed 2025-08-14 | $9.14M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $467.85K 10-Q · filed 2025-05-08 | $4.02M derived: sum of 2 quarters · filed 2025-05-08 | $6.48M derived: sum of 3 quarters · filed 2025-05-08 | $6.68M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $3.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $6.01M derived: sum of 2 quarters · filed 2025-03-27 | $6.21M derived: sum of 3 quarters · filed 2025-03-27 | $6.81M 10-K · filed 2025-03-27 |
| 2023-09-30 | $2.46M 10-Q · filed 2024-11-07 | $2.65M derived: sum of 2 quarters · filed 2024-11-07 | $3.26M 10-Q · filed 2024-11-07 | $4.66M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $197.81K 10-Q · filed 2024-08-08 | $799.76K 10-Q · filed 2024-08-08 | $2.20M derived: sum of 3 quarters · filed 2024-08-08 | $7.30M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $601.96K 10-Q · filed 2024-05-09 | $2.00M derived: sum of 2 quarters · filed 2024-05-09 | $7.10M derived: sum of 3 quarters · filed 2024-05-09 | $12.12M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $6.50M derived: sum of 2 quarters · filed 2024-03-14 | $11.52M derived: sum of 3 quarters · filed 2024-03-14 | $34.22M 10-K · filed 2024-03-14 |
| 2022-09-30 | $5.09M 10-Q · filed 2023-11-09 | $10.12M derived: sum of 2 quarters · filed 2023-11-09 | $32.82M 10-Q · filed 2023-11-09 | $53.22M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $5.02M 10-Q · filed 2023-08-10 | $27.72M 10-Q · filed 2023-08-10 | $48.12M derived: sum of 3 quarters · filed 2023-08-10 | $78.22M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $22.70M 10-Q · filed 2023-05-11 | $43.10M derived: sum of 2 quarters · filed 2023-05-11 | $73.20M derived: sum of 3 quarters · filed 2023-05-11 | $100.56M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $20.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $50.50M derived: sum of 2 quarters · filed 2023-03-16 | $77.86M derived: sum of 3 quarters · filed 2023-03-16 | $97.89M 10-K · filed 2023-03-16 |
| 2021-09-30 | $30.10M 10-Q · filed 2022-11-10 | $57.46M derived: sum of 2 quarters · filed 2022-11-10 | $77.48M 10-Q · filed 2022-11-10 | $104.63M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $27.36M 10-Q · filed 2022-08-11 | $47.38M 10-Q · filed 2022-08-11 | $74.53M derived: sum of 3 quarters · filed 2022-08-11 | $96.35M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $20.02M 10-Q · filed 2022-05-12 | $47.17M derived: sum of 2 quarters · filed 2022-05-12 | $68.99M derived: sum of 3 quarters · filed 2022-05-12 | $93.03M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $27.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $48.96M derived: sum of 2 quarters · filed 2022-03-24 | $73.00M derived: sum of 3 quarters · filed 2022-03-24 | $74.55M 10-K · filed 2022-03-24 |
| 2020-09-30 | $21.82M 10-Q · filed 2021-11-12 | $45.86M derived: sum of 2 quarters · filed 2021-11-12 | $47.41M 10-Q · filed 2021-11-12 | $47.52M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $24.04M 10-Q · filed 2021-08-12 | $25.59M 10-Q · filed 2021-08-12 | $25.70M derived: sum of 3 quarters · filed 2021-08-12 | $25.74M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $1.55M 10-Q · filed 2021-05-13 | $1.66M derived: sum of 2 quarters · filed 2021-05-13 | $1.70M derived: sum of 3 quarters · filed 2021-05-13 | |
| 2019-12-31 | $108.57K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $150.00K derived: sum of 2 quarters · filed 2021-03-25 | $214.97K 10-K · filed 2021-03-25 | |
| 2019-09-30 | $41.43K 10-Q · filed 2020-11-16 | $106.41K 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| ALLURION TECHNOLOGIES, INC. (ALUR) | United States | $0.010B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Picard Medical, Inc. (PMI) | United States | $0.011B | -0.01 |